DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

September 2, 2023

PROSPECT PCNSL Study

Prospect logo

ENROLL NOW: CLINICAL TRIAL FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)

Today, the End Brain Cancer Initiative (EBCI) and I want to make you aware of a clinical trial, The PROSPECT Study, that is enrolling for a type of LYMPHOMA known as Primary Central Nervous System Lymphoma or PCNSL.

PROSPECT is an open-label, Phase II study that is evaluating the efficacy, safety and pharmacokinetics of an oral medicine called tyrosine kinase (BTK) inhibitor in patients with PCNSL as currently there are no medications FDA approved in the U.S. specifically for the treatment of this disease. About 112 patients will be enrolled in this trial in the U.S.

To learn more, please go to www.EndBrainCancer.org, review our web landing page for the PROSPECT trial, sponsored by Ono Pharma USA, Inc. and fill out our “Advocacy & Patient Inquiry” form so that we can call and email you with additional information as well as “Directly Connect” you to the site and doctor that has this trial open/enrolling closest to where you live in the U.S. Some sites that are currently enrolling for this trial are:

City of Hope - Comprehensive Breast Cancer Center - Duarte, CA
Contact: Avyakta Kallam | 626-218-8276 | akallam@coh.org

University of California - Irvine, CA
Contact: Daniela Bota | 714-456-7214 | dbota@hs.uci.edu

Stanford University - Palo Alto, CA 
Contact: Neel Gupta | 650-7245361 | neelkg@stanford.edu

University of Colorado Denver - Aurora, CO
Contact: Denise Damek | 720-848-8312 | denise.damek@ucdenver.edu

Yale Cancer Center - New Haven, CT
Contact: Antonio Omuro | 475-202-3955 | antonio.omuro@yale.edu

Additional Information on this clinical trial can also be found here: https://clinicaltrials.gov/study/NCT04947319?id=NCT04947319&rank=1

Blessings,

Dellann Signature
Dellann photo

Dellann Elliott Mydland
President & CEO

The EndBrainCancer Initiative | Chris Elliott Fund
16150 NE 85th St #201
Redmond WA 98052

Dellann@EndBrainCancer.org
www.EndBrainCancer.org

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram